학술논문
Drug‐refractory myasthenia gravis: Clinical characteristics, treatments, and outcome
Document Type
article
Author
Elena Cortés‐Vicente; Rodrigo Álvarez‐Velasco; Francesc Pla‐Junca; Ricard Rojas‐Garcia; Carmen Paradas; Teresa Sevilla; Carlos Casasnovas; María Teresa Gómez‐Caravaca; Julio Pardo; Alba Ramos‐Fransi; Ana Lara Pelayo‐Negro; Gerardo Gutiérrez‐Gutiérrez; Janina Turon‐Sans; Adolfo López de Munain; Antonio Guerrero‐Sola; Ivonne Jericó; María Asunción Martín; María Dolores Mendoza; Germán Morís; Beatriz Vélez‐Gómez; Tania Garcia‐Sobrino; Elba Pascual‐Goñi; David Reyes‐Leiva; Isabel Illa; Eduard Gallardo
Source
Annals of Clinical and Translational Neurology, Vol 9, Iss 2, Pp 122-131 (2022)
Subject
Language
English
ISSN
2328-9503
Abstract
Abstract Objective To describe the clinical characteristics and outcomes in patients with refractory myasthenia gravis (MG) and to determine the effectiveness and side effects of the drugs used for their treatment. Methods This observational retrospective cross‐sectional multicenter study was based on data from the Spanish MG Registry (NMD‐ES). Patients were considered refractory when their MG Foundation of America post‐interventional status (MGFA‐PIS) was unchanged or worse after corticosteroids and two or more other immunosuppressive agents. Clinical and immunologic characteristics of drug‐refractory patients, efficiency and toxicity of drugs used, and outcome (MGFA‐PIS) at end of follow‐up were studied. Results We included 990 patients from 15 hospitals. Eighty‐four patients (68 of 842 anti‐acetylcholine receptor [AChR], 5 of 26 anti‐muscle‐specific tyrosine kinase [MusK], 10 of 120 seronegative, and 1 of 2 double‐seropositive patients) were drug refractory. Drug‐refractory patients were more frequently women (p